Contributions of multimodal imaging

per Oyen, Wim JG
Publicat a Cancer Imaging (2014)

Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer

per Fanti, Stefano, Oyen, Wim, Lalumera, Elisabetta
Publicat a Cancers (Basel) (2019)

FIAU: From reporter gene imaging to imaging of bacterial proliferation

per Boerman, Otto C, Laverman, Peter, Oyen, Wim JG
Publicat 2012

Predictive and prognostic value of FDG-PET

per de Geus-Oei, Lioe-Fee, Oyen, Wim J.G.
Publicat 2008

Nuclear medicine imaging and therapy of neuroendocrine tumours

per Gotthardt, Martin, Dijkgraaf, Ingrid, Boerman, Otto C, Oyen, Wim J G
Publicat 2006

Gastroparesis in patients with inactive Crohn's disease: a case series

per Kristinsson, Jón O, Hopman, Wim PM, Oyen, Wim JG, Drenth, Joost PH
Publicat 2007

Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with (111)In in HEPES and MES buffer

per Brom, Maarten, Joosten, Lieke, Oyen, Wim JG, Gotthardt, Martin, Boerman, Otto C
Publicat 2012

Radiolabelled peptides for oncological diagnosis

per Laverman, Peter, Sosabowski, Jane K., Boerman, Otto C., Oyen, Wim J. G.
Publicat 2012

Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies

per Koppe, Manuel J., Boerman, Otto C., Oyen, Wim J. G., Bleichrodt, Robert P.
Publicat 2006

Peritoneal Carcinomatosis of Colorectal Origin: Standard of Care

per Koppe, Manuel J., Boerman, Otto C., Oyen, Wim J. G., Bleichrodt, Robert P.
Publicat 2006

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

per Brom, Maarten, Oyen, Wim J. G., Joosten, Lieke, Gotthardt, Martin, Boerman, Otto C.
Publicat 2010

Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas

per Brom, Maarten, Joosten, Lieke, Oyen, Wim J.G., Gotthardt, Martin, Boerman, Otto C.
Publicat a Contrast Media Mol Imaging (2012)

FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment

per Quak, Elske, Kovacs, Iringo, Oyen, Wim J. G., van der Graaf, Winette T. A.
Publicat a Nucl Med Mol Imaging (2015)

Methodological considerations in quantification of oncological FDG PET studies

per Vriens, Dennis, Visser, Eric P., de Geus-Oei, Lioe-Fee, Oyen, Wim J. G.
Publicat 2009

Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations

per van Dalen, Jorn A., Vogel, Wouter V., Corstens, Frans H.M., Oyen, Wim J.G.
Publicat 2007

Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study

per Schinagl, Dominic A. X., Span, Paul N., Oyen, Wim J., Kaanders, Johannes H. A. M.
Publicat 2011

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma

per Gilles, Rozemarie, de Geus-Oei, Lioe-Fee, Mulders, Peter F. A., Oyen, Wim J. G.
Publicat 2011

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems

per Kaalep, Andres, Sera, Terez, Oyen, Wim, Krause, Bernd J., Chiti, Arturo, Liu, Yan, Boellaard, Ronald
Publicat a Eur J Nucl Med Mol Imaging (2017)

Radiolabeled antibodies in renal cell carcinoma

per Stillebroer, Alexander B., Oosterwijk, Egbert, Oyen, Wim J.G., Mulders, Peter F.A., Boerman, Otto C.
Publicat 2007

Antibody therapy in renal cell carcinoma

per Oosterwijk, Egbert, Boerman, Otto C., Oyen, Wim J. C., Old, Lloyd J., Mulders, Peter F. A.
Publicat 2008